EPA:ALTHX - Euronext Paris - Matif - FR0013286259 - Common Stock - Currency: EUR
EPA:ALTHX (3/7/2025, 7:00:00 PM)
0.49
+0.01 (+2.51%)
The current stock price of ALTHX.PA is 0.49 EUR. In the past month the price decreased by -9.26%. In the past year, price decreased by -55.13%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
1PFE.MI | PFIZER INC | 8.6 | 139.42B |
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 12 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
THERANEXUS SADIR
60, Avenue Rockefeller - Pepiniere Laennec
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 17
Company Website: https://www.theranexus.com/
Investor Relations: http://www.theranexus.com/fr/actionnaires/documents.html
Phone: 33188897031
The current stock price of ALTHX.PA is 0.49 EUR. The price increased by 2.51% in the last trading session.
The exchange symbol of THERANEXUS SADIR is ALTHX and it is listed on the Euronext Paris - Matif exchange.
ALTHX.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALTHX.PA and the average price target is 6.32 EUR. This implies a price increase of 1190.61% is expected in the next year compared to the current price of 0.49. Check the THERANEXUS SADIR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
THERANEXUS SADIR (ALTHX.PA) has a market capitalization of 3.80M EUR. This makes ALTHX.PA a Nano Cap stock.
THERANEXUS SADIR (ALTHX.PA) currently has 17 employees.
THERANEXUS SADIR (ALTHX.PA) has a support level at 0.46 and a resistance level at 0.5. Check the full technical report for a detailed analysis of ALTHX.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALTHX.PA does not pay a dividend.
THERANEXUS SADIR (ALTHX.PA) will report earnings on 2025-04-29, after the market close.
THERANEXUS SADIR (ALTHX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
ChartMill assigns a fundamental rating of 1 / 10 to ALTHX.PA. ALTHX.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ALTHX.PA reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 68.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -72.26% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ALTHX.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.